Journal Information
Vol. 100. Issue 3.
Pages 212-221 (April 2009)
Share
Share
Download PDF
More article options
Vol. 100. Issue 3.
Pages 212-221 (April 2009)
Original articles
Full text access
Therapeutic Effectiveness of Psoralen-U V-A Bath Therapy In Psoriasis
Eficacia Terapéutica del Baño-PUVA en Psoriasis
Visits
5699
M.T. Rodríguez-Granadosa,
Corresponding author
trgranados@mundo-r.com

Correspondence. Servicio de Dermatología. Complejo Hospitalario Universitario de Santiago de Compostela. Facultad de Medicina. Universidad de Compostela. 15707 Santiago de Compostela. A Coruña. Spain.
, M.J. Pereira-Rodríguezb, F.L. Vázquez-Vizosoc
a Servicio de Dermatología. Complejo Universitario Juan Canalejo. A Coruña
b Servicio de Medicina Preventiva. Complejo Universitario Juan Canalejo. A Coruña
c Servicio de Medicina Preventiva. Complexo Hospitalario de Pontevedra. Spain
This item has received
Article information
Abstract
Introduction

The use of psoralen baths with long-wave UV radiation, known as PUVA bath therapy, is useful in the treatment of psoriasis. The therapy is not associated with systemic adverse effects and the dose of UV-A radiation administered is lower. The objectives of this study aimed to identify the variables that influence the effectiveness of PUVA bath therapy and the duration of remission, as well as to determine factors that predict relapse. It also aimed to assess the effectiveness of a protocol using the minimal phototoxic dose and to compare two concentrations of 8-methoxypsoralen.

Patients and methods

Two hundred nine patients with moderate-severe plaque psoriasis attended between 1994 and 2000 were included in the study. The characteristics and therapeutic outcomes of the sample were recorded. Survival curves were plotted for the disease-free interval after a good response to treatment. A proportional hazard model was used to assess the factors that influence the duration of remission.

Results

Therapeutic outcomes were better in patients with greater photosensitivity (p = 0.03). Application of the minimal phototoxic dose protocol was not associated with greater phototoxicity during treatment. The median duration of remission was 7 months. Those patients who had previously undergone oral PUVA therapy and those who did not achieve a substantial reduction in the psoriasis area and severity index (PASI) score were at greater risk of relapse.

Conclusions

A lower final PASI extended the lesion-free period.

Key words:
psoriasis
photosensitivity
photochemotherapy
psoralen-UV-A bath therapy
therapeutic effectiveness
Resumen
Introducción

El baño de psoralenos (P) e irradiación con ultravioleta de onda larga (UVA), conocido como baño-PUVA, es útil en el tratamiento de la psoriasis con la ausencia de efectos adversos sistémicos y una menor dosis de UVA administrada. El objetivo de este trabajo es identificar las variables que influyen en la efectividad del tratamiento con baño-PUVA y el período de remisión, así como determinar aquellas que permitan predecir la recidiva; valorar la efectividad de la prueba de fototoxicidad cutánea(DFM), y comparar dos concentraciones del 8-metoxipsoraleno (8-MOP).

Pacientes y métodos

Se incluyeron 209 pacientes afectos de psoriasis en placas moderada-grave visitados en el período 1994-2000. Se realizó un estudio descriptivo de las características y resultados terapéuticos de lamuestra estudiada, y un estudio de supervivencia valorando el tiempo libre de enfermedad tras una buena respuesta al tratamiento. El análisis 0de riesgos proporcionales permitió evaluar qué factores influyeron en el período de remisión.

Resultados

Los pacientes con mayor fotosensibilidad mostraron los mejores resultados terapéuticos (p = 0,03). El protocolo en que se realizó la DFM no supuso más fototoxicidad durante el tratamiento. La duración del período de remisión fue de 7 meses en el 50% de los pacientes. Aquellos pacientes que previamente realizaron terapia PUVA oral, y los que no consiguieron una reducción importante del Psoriasis Area and Severity Index (PASI), condicionaron un mayor riesgo de recidiva.

Conclusiones

Un PASI final reducido incrementa la duración del tiempo libre de lesiones.

Palabras clave:
psoriasis
fotosensibilidad
fotoquimioterapia
baño-PUVA
eficacia terapéutica
Full text is only aviable in PDF
References
[1.]
C. Ferrándiz, X. Bordas, V. García-Patos, S. Puig, R. Pujol, A. Smandía.
Prevalence of psoriasis in Spain (Epiderma Project: phase I).
J Eur Acad Dermatol Venereol, 15 (2001), pp. 20-23
[2.]
J. Parrish, T. Fitzpatrick, L. Tanenbaum, M. Pathak.
Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light.
N Engl J Med, 291 (1974), pp. 1207-1211
[3.]
T. Fischer, J. Alsins.
Treatment of psoriasis with trioxsalen baths and dysprosium lamps.
Acta Derm Venereol, 56 (1976), pp. 383-390
[4.]
N. Väätäinen, M. Hannuksela, J. Karvonen.
Long-term local trioxsalen photochemotherapy in psoriasis.
Dermatology, 163 (1981), pp. 229-231
[5.]
J. Lauharanta, J. Geiger.
A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis.
Br J Dermatol, 121 (1989), pp. 107-112
[6.]
J. Schmitt, W. Gottfried.
The psoriasis area and severity index is the adequate criterion to define severity in chronic plaquetype psoriasis.
Dermatology, 210 (2005), pp. 194-199
[7.]
J. Carrascosa, J. Gardeazábal, A. Pérez-Ferriols, A. Alomar, P. Manrique, M. Jones-Caballero, et al.
Documento de consenso sobre fototerapia: terapias PUVA y UVB de banda estrecha.
Actas Dermosifiliogr, 96 (2005), pp. 635-658
[8.]
M. Gómez, B. Pérez, A. Harto, R. De Misa, A. Ledo.
8-MOP bath PUVA in the treatment of psoriasis: Clinical results in 42 patients.
J Dermatol Treat, 7 (1996), pp. 11-12
[9.]
S. Karrer, C. Eholzer, G. Ackermann, M. Landthaler, R.M. Szeimies.
Phototherapy of psoriasis: comparative experience of different phototherapeutic approaches.
Dermatology, 202 (2001), pp. 108-115
[10.]
S. Halpern, A. Anstey, R. Dawe, B. Diffey, P. Farr, J. Ferguson, et al.
Guidelines for topical PUVA: a report of a workshop of the British Photodermatology Group.
Br J Dermatol, 142 (2000), pp. 22-31
[11.]
E. Farber, L. Nall, W. Watson.
Natural history of psoriasis in 61 twin pairs.
Arch Dermatol, 109 (1974), pp. 207-211
[12.]
C. Ferrándiz, R. Pujol, V. García-Patos, X. Bordas, J. Smandía.
Psoriasis of early and late onset: A clinical and epidemiologic study from Spain.
J Am Acad Dermatol, 46 (2002), pp. 867-873
[13.]
T. Henseler, E. Christophers.
Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris.
J AmAcad Dermatol, 15 (1985), pp. 450-456
[14.]
S. Yones, R. Palmer, T. Garibaldinos, J. Hawk.
Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy.
Arch Dermatol, 142 (2006), pp. 836-842
[15.]
G. Von Kobyletzki, K. Hoffmann, M. Kerscher, P. Altmeyer.
Plasma levels of 8-methoxypsoralen following PUVA-bath photochemotherapy.
Photodermatol Photoimmunol Photomed, 14 (1998), pp. 136-138
[16.]
N. Cox, P. Farr, B. Diffey.
A comparison of the dose-response relationship for psoralen-UVA erythema and UVB erythema.
Arch Dermatol, 125 (1989), pp. 1653-1657
[17.]
P. Calzavara-Pinton, B. Ortel, H. Honigsmann, C. Zane, G. De Panfilis.
Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis.
Dermatology, 189 (1994), pp. 256-259
[18.]
T. Reuther, C. Gruss, S. Behrens, G. von Kobyletzki, N. Neumann, P. Lehmann, et al.
Time course of 8-methoxypsoraleninduced skin photosensitization in PUVA-bath photochemotherapy.
Photodermatol Photoimmunol Photomed, 13 (1997), pp. 193-196
[19.]
P. Calzavara-Pinton, B. Ortel, A. Carlino, H. Honigsmann, G. De Panfilis.
Phototesting and phototoxic side effects in bath PUVA.
J Am Acad Dermatol, 28 (1993), pp. 657-659
[20.]
E. Cooper, R. Herd, G. Priestley, J. Hunter.
A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis.
Clin Exp Dermatol, 25 (2000), pp. 111-114
[21.]
R. Schiener, S. Behrens-Williams, H. Pillekamp, R. Peter, M. Kerscher.
Does the minimal phototoxic dose after8-methoxypsoralen baths correlate with the individual's skin phototype ?.
Photodermatol Photoimmunol Photomed, 17 (2001), pp. 156-158
[22.]
D. Bilsland, R. Dawe.
Ultraviolet phototherapy and photochemotherapy of skin disease.
Photodermatology, pp. 113-124
[23.]
I. Tegeder, L. Bräutigam, M. Podda, S. Meier, R. Kaufmann, G. Geisslinger, et al.
Time course of 8-methoxypsoralen concentrations in skin and plasma after topical (bath and cream) and oral administration of 8-methoxypsoralen.
Pharmacol Ther, 71 (2002), pp. 153-161
[24.]
U. Kappes, U. Barta, U. Merkel, A. Balogh, P. Elsner.
High plasma levels of 8-methoxypsoralen following bath water delivery in dermatological patients.
Skin Pharmacol Appl Skin Physiol, 16 (2003), pp. 305-312
[25.]
A. Tanew, T. Kipfelsperger, A. Seeber, S. Radakovic-Fijan, H. Hönigsmann.
Correlation between 8-methoxypsoralen bath-water concentration and photosensitivity inbath-PUVA treatment.
J Am Acad Dermatol, 44 (2001), pp. 638-642
[26.]
R. Vongthongsri, R. Konschitzky, A. Seeber, C. Treitl, H. Hönigsmann, A. Tanew.
Randomized, double-blind comparison of 1 mg/L versus 5 mg/L methoxsalen bath- PUVA therapy for chronic plaque-type psoriasis.
J Am Acad Dermatol, 55 (2006), pp. 627-631
[27.]
K. Degitz, G. Plewig, M. Röcken.
Rapid decline in photosensitivity after 8-methoxypsoralen bathwater delivery.
Arch Dermatol, 132 (1996), pp. 1394-1395
[28.]
N. Neumann, M. Kerscher, T. Ruzicka, P. Lehmann.
Evaluation of PUVA bath phototoxicity.
Acta Derm Venereol, 77 (1997), pp. 385-387
[29.]
E. Dolezal, A. Seeber, H. Hönigsmann, A. Tanew.
Correlation between bathing time and photosensitivity in 8-methoxypsoralen (8-MOP) bath PUVA.
Photodermatol Photoimmunol Photomed, 16 (2000), pp. 183-185
[30.]
P. Collins, S. Rogers.
Bath-water delivery of 8-methoxypsoralen therapy for psoriasis.
Clin Exp Dermatol, 16 (1991), pp. 165-167
[31.]
L. Koulu, C. Jansén.
Skin phototoxicity variations during repeated bath PUVA exposures to 8-methoxypsoralen and trimethyl psoralen.
Clin Exp Dermatol, 9 (1984), pp. 64-69
[32.]
C. Schempp, E. Schöpf, J. Simon.
Phototesting in bath-PUVA: marked reduction of 8-methoxypsoralen (8-MOP) activity within one hour after an 8-MOP bath.
Photodermatol Photoimmunol Photomed, 12 (1996), pp. 100-102
[33.]
N. Lowe, D. Weingarten, T. Bourget, L. Moy.
PUVA therapy for psoriasis: Comparison of oral and bath-water delivery of 8-methoxypsoralen.
J Am Acad Dermatol, 14 (1986), pp. 754-760
[34.]
H. Hönigsmann, A. Tanew, T. Ruzicka, W. Morison.
Photo(chemo) therapy for psoriasis.
Dermatological Phototherapy and Photodiagnostic Methods, 1st ed, pp. 72-81
[35.]
D. Buckley, E. Healy, S. Rogers.
A comparison of twice-weekly MPD-PUVA and three times-weekly skin typing-PUVA regimens for the treatment of psoriasis.
Br J Dermatol, 133 (1995), pp. 417-422
[36.]
B. Kirby, D. Buckley, S. Rogers.
Large increments in psoralenultraviolet A (PUVA) therapy are unsuitable for fair-skinned individuals with psoriasis.
Br J Dermatol, 140 (1999), pp. 661-666
[37.]
I. Man, R. Dawe, J. Ferguson, S. Ibbotson.
An intraindividual study of the characteristics of erythema induced by bath and oral methoxsalen photochemotherapy and narrowband ultraviolet B.
Photochem Photobiol, 78 (2003), pp. 55-60
[38.]
K. Turjanmaa, H. Salo, T. Reunala.
Comparison of trioxsalen bath and oral methoxsalen PUVA in psoriasis.
Acta Derm Venereol, 65 (1985), pp. 86-88
[39.]
P. Collins, N. Wainwright, I. Amorim, T. Lakshmipathi, J. Ferguson.
8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach.
Br J Dermatol, 135 (1996), pp. 248-254

This article is the result of the doctoral thesis of María Teresa Rodríguez Granados, “Therapeutic Effectiveness of Psoralen-UV-A Bath in Psoriasis: First Study in the Autonomous Community of Galicia, Spain.

Copyright © 2009. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
Idiomas
Actas Dermo-Sifiliográficas
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?